Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.

JCI Insight. 2019 Apr 4;4(7). pii: 126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.

2.

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.

Hamilton DH, McCampbell KK, Palena C.

Front Oncol. 2018 May 3;8:143. doi: 10.3389/fonc.2018.00143. eCollection 2018.

3.

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C.

Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.

4.

Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.

Dominguez C, McCampbell KK, David JM, Palena C.

JCI Insight. 2017 Nov 2;2(21). pii: 94296. doi: 10.1172/jci.insight.94296.

5.

Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Shah SR, David JM, Tippens ND, Mohyeldin A, Martinez-Gutierrez JC, Ganaha S, Schiapparelli P, Hamilton DH, Palena C, Levchenko A, Quiñones-Hinojosa A.

Cell Rep. 2017 Oct 10;21(2):495-507. doi: 10.1016/j.celrep.2017.09.057.

6.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

7.

The adverse effect of overweight in assisted reproduction treatment outcomes.

Sampo AV, Palena C, Ganzer L, Maccari V, Estofán G, Hernández M.

JBRA Assist Reprod. 2017 Sep 1;21(3):212-216. doi: 10.5935/1518-0557.20170041.

8.

Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Dominguez C, David JM, Palena C.

Semin Cancer Biol. 2017 Dec;47:177-184. doi: 10.1016/j.semcancer.2017.08.002. Epub 2017 Aug 18. Review.

9.

Feline leukocyte adhesion (CD18) deficiency caused by a deletion in the integrin β2 (ITGB2) gene.

Bauer TR Jr, Pratt SM, Palena CM, Raj K, Giger U.

Vet Clin Pathol. 2017 Sep;46(3):391-400. doi: 10.1111/vcp.12526. Epub 2017 Jul 27.

10.

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.

11.

Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.

Hamilton DH, David JM, Dominguez C, Palena C.

Cells Tissues Organs. 2017;203(2):128-138. doi: 10.1159/000446495. Epub 2017 Feb 20. Review.

12.

Pharmacological and immunological targeting of tumor mesenchymalization.

David JM, Dominguez C, Palena C.

Pharmacol Ther. 2017 Feb;170:212-225. doi: 10.1016/j.pharmthera.2016.11.011. Epub 2016 Dec 1. Review.

13.

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.

Dominguez C, Tsang KY, Palena C.

Cell Death Dis. 2016 Sep 29;7(9):e2380. doi: 10.1038/cddis.2016.297.

14.

Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

Hamilton DH, Roselli M, Ferroni P, Costarelli L, Cavaliere F, Taffuri M, Palena C, Guadagni F.

Endocr Relat Cancer. 2016 Oct;23(10):783-796. doi: 10.1530/ERC-16-0037.

15.

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance.

David JM, Dominguez C, Hamilton DH, Palena C.

Vaccines (Basel). 2016 Jun 24;4(3). pii: E22. doi: 10.3390/vaccines4030022. Review.

16.

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.

Hamilton DH, Griner LM, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M, Palena C.

Clin Cancer Res. 2016 Dec 15;22(24):6204-6216. Epub 2016 Jun 7.

17.

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C.

Oncotarget. 2016 Jul 5;7(27):42031-42044. doi: 10.18632/oncotarget.9662.

18.

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.

David JM, Hamilton DH, Palena C.

Oncoimmunology. 2016 Jan 6;5(4):e1117738. eCollection 2016 Apr.

19.

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, Schlom J.

Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.

20.

Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.

Palena C, Hamilton DH.

Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12. Review.

Supplemental Content

Loading ...
Support Center